Clinical Trial Update: Non-alcoholic Steatohepatitis Registry Platform Study

View source ↗

Summary

AstraZeneca’s registry platform trial for non-alcoholic steatohepatitis with fibrosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis with Fibrosis

Snippet

Sponsor: AstraZeneca | Conditions: NASH With Fibrosis | Status: TERMINATED